Diffuse large B-cell lymphoma (DLBCL)

• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 4 2025-05-16
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly … Recruiting
  2023-505377-32-00 5 2024-08-15
• A Phase 3 study of Tafasitamab plus Lenalidomide in patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Recruitment ended
  2023-505579-53-00 5 2022-10-25
• A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom … Recruitment ended
  2022-501380-40-00 4 2022-08-10
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Recruitment ended
  2023-503916-33-00 5 2021-03-24
• A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with pre … Ended
  2024-517166-42-00 4 2020-05-29
• Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch … Ended
  2023-507498-16-00 9 2019-07-02

Showing 1–11 of 11 trials